ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Edaravone

Also written as “MT-1186”, “MCI-186” and “Continuous infusion high-dose MCI-186”.

Its studies are mostly in Amyotrophic Lateral Sclerosis · Ischemic Stroke · Cerebral Infarction · Renal Insufficiency · Ischemia, led by 4 companies.

Drug pageEdaravone: every studyAll 38 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Sep 12, 200526 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shionogiits history only230 open or runningphase 4since Sep 12, 2005Sep 12, 2005none ahead
Jiangsu HengRui Medicineits history only10 open or runningphase 1since Jul 16, 2025Jul 16, 2025none ahead
Nanjing Yoko Biomedical10 open or runningphase 1since Dec 17, 2019Dec 17, 2019none ahead
Shanghai Auzone Biological Technologyits history only10 open or runningphase 1since Oct 16, 2023Oct 16, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Nanjing Yoko Biomedical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2019First study: phase 1 study in Drug-drug InteractionFirst studyNCT04218513 · 24 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Nanjing Yoko Biomedical leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04218513Drug-drug Interaction · China1CompletedMay 31, 201924

How it is read

Names in the registry

  • “MT-1186”, 12 entries
  • “MCI-186”, 10 entries
  • “Edaravone”, 1 entry
  • “Continuous infusion high-dose MCI-186”, 1 entry
  • “Continuous infusion low-dose MCI-186”, 1 entry

Codes read as this program: MT1186, MCI186.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.